- Home
- CBNA vs ENTA Comparison
CBNA vs ENTA Comparison
Compare CBNA & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBNA
- ENTA
- Stock Information
- Founded
- CBNA 2006
- ENTA 1995
- Country
- CBNA United States
- ENTA United States
- Employees
- CBNA N/A
- ENTA N/A
- Industry
- CBNA
- ENTA Biotechnology: Pharmaceutical Preparations
- Sector
- CBNA
- ENTA Health Care
- Exchange
- CBNA NYSE
- ENTA Nasdaq
- Market Cap
- CBNA 159.8M
- ENTA 154.0M
- IPO Year
- CBNA 2024
- ENTA 2013
- Fundamental
- Price
- CBNA $25.94
- ENTA $5.27
- Analyst Decision
- CBNA Buy
- ENTA Buy
- Analyst Count
- CBNA 3
- ENTA 4
- Target Price
- CBNA $29.67
- ENTA $17.25
- AVG Volume (30 Days)
- CBNA 12.6K
- ENTA 194.0K
- Earning Date
- CBNA 04-28-2025
- ENTA 05-20-2025
- Dividend Yield
- CBNA N/A
- ENTA N/A
- EPS Growth
- CBNA 59.84
- ENTA N/A
- EPS
- CBNA 4.10
- ENTA N/A
- Revenue
- CBNA $57,087,000.00
- ENTA $66,590,999.00
- Revenue This Year
- CBNA N/A
- ENTA N/A
- Revenue Next Year
- CBNA $22.92
- ENTA N/A
- P/E Ratio
- CBNA $6.34
- ENTA N/A
- Revenue Growth
- CBNA 62.88
- ENTA N/A
- 52 Week Low
- CBNA $20.01
- ENTA $4.09
- 52 Week High
- CBNA $27.56
- ENTA $17.24
- Technical
- Relative Strength Index (RSI)
- CBNA N/A
- ENTA 45.38
- Support Level
- CBNA N/A
- ENTA $4.96
- Resistance Level
- CBNA N/A
- ENTA $6.23
- Average True Range (ATR)
- CBNA 0.00
- ENTA 0.33
- MACD
- CBNA 0.00
- ENTA -0.01
- Stochastic Oscillator
- CBNA 0.00
- ENTA 24.41
About CBNA CHAIN BRIDGE BANCORP INC
Chain Bridge Bancorp Inc is engaged in banking industry. It offers commercial and personal banking services, including deposits, treasury management, payments, loans, commercial lending, residential mortgage financing, consumer loans, trusts and estate administration, wealth management, and asset custody.
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.